Skip to main content

Table 2 Surgical outcomes for patients with primary malignant melanoma of esophagus

From: Clinical characteristics and treatment outcomes of primary malignant melanoma of esophagus: a single center experience

No

Age

Sex

Surgery type

Tumor location

Tumor morphology

Tumor size (pathology, cm)

Tumor depth (pathology)

LNM

Resection margin

BRAF

PD-L1 (TPS)

Adjuvant therapy

Disease-free survival (months)

Recurrent organ

Overall survival (months)

Outcome

1

48

M

3-field

Upper

DI

0.8

SM

0/13

Negative

Not detected

N/A

No

36

Anastomosis

59

Dead

2

53

F

I-L

Middle

MF

7.5

SM

0/33

Negative

Not detected

N/A

No

15

Femur, lung

38

Dead

3

70

M

I-L

Lower

MF

8.5

PM

2/46

Negative

N/A

30%

Pembrolizumab

4

Peritoneum

25

Alive

4

41

F

I-L

Lower

MF

2.2

SM

3/21

Negative

N/A

N/A

N/A

N/A

N/A

22

Alive

5

65

M

TG

EGJ

MF

4.0

SM

9/40

Negative

N/A

N/A

IFN-α

4

Anastomosis, liver

11

Dead

6

51

M

I-L

Lower

MF

6.0

PM

4/17

Negative

Not detected

1%

Pembrolizumab

3

LN, peritoneum, abdominal wall

9

Dead

7

77

M

I-L

Lower

MF

9.0

PM

9/25

Negative

N/A

N/A

No

5

Anastomosis, liver, peritoneum

8

Dead

8

69

M

I-L

Lower

MF

3.5

SM

0/7

Negative

Not detected

N/A

IFN-α

4

Neo-esophagus

7

Dead

9

57

M

3-field

Middle

MF

4.5

SM

5/80

Negative

Not detected

N/A

RT followed by IFN-α

1

Supraclavicular LN

6

Dead

10

53

M

I-L

Lower

MF

3.5

SM

0/36

Negative

N/A

N/A

No

4

Brain

6

Dead

  1. LNM lymph node metastases, PD-L1 programmed death-ligand 1, TPS tumor proportion score, M male, F female, DI diffusely infiltrative, MF mass-forming, I-L Ivor-Lewis operation, TG total gastrectomy, EGJ esophagogastric junction, SM submucosa, PM muscularis propria, RT radiotherapy, IFN-α interferon-alpha, N/A not available